Saltar al contenido
Merck

Redefining Perineural Invasion: Integration of Biology With Clinical Outcome.

Neoplasia (New York, N.Y.) (2018-05-26)
Ligia B Schmitd, Lauren J Beesley, Nickole Russo, Emily L Bellile, Ronald C Inglehart, Min Liu, Genevieve Romanowicz, Gregory T Wolf, Jeremy M G Taylor, Nisha J D'Silva
RESUMEN

A diagnosis of perineural invasion (PNI), defined as cancer within or surrounding at least 33% of the nerve, leads to selection of aggressive treatment in squamous cell carcinoma (SCC). Recent mechanistic studies show that cancer and nerves interact prior to physical contact. The purpose of this study was to explore cancer-nerve interactions relative to clinical outcome. Biopsy specimens from 71 patients with oral cavity SCC were stained with hematoxylin and eosin and immunohistochemical (IHC; cytokeratin, S100, GAP43, Tuj1) stains. Using current criteria, PNI detection was increased with IHC. Overall survival (OS) tended to be poor for patients with PNI (P = .098). OS was significantly lower for patients with minimum tumor-nerve distance smaller than 5 μm (P = .011). The estimated relative death rate decreased as the nerve-tumor distance increased; there was a gradual drop off in death rate from distance equal to zero that stabilized around 500 μm. In PNI-negative patients, nerve diameter was significantly related to OS (HR 2.88, 95%CI[1.11,7.49]). Among PNI-negative nerves, larger nerve-tumor distance and smaller nerve diameter were significantly related to better OS, even when adjusting for T-stage and age (HR 0.82, 95% CI[0.72,0.92]; HR 1.27, 95% CI[1.00,1.62], respectively). GAP43, a marker for neuronal outgrowth, stained less than Tuj1 in nerves at greater distances from tumor (OR 0.76, 95% CI[0.73,0.79]); more GAP43 staining was associated with PNI. Findings from a small group of patients suggest that nerve parameters other than presence of PNI can influence outcome and that current criteria of PNI need to be re-evaluated to integrate recent biological discoveries.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anti-β-Tubulin III (neuronal) antibody, Mouse monoclonal, ~1.0 mg/mL, clone 2G10, purified from hybridoma cell culture
Sigma-Aldrich
IHC Select Anti-Cytokeratin AE1/AE3 (Pan cytokeratins) Antibody, prediluted, clone AE1/AE3, clone AE1/AE3, from mouse